Journal Logo

Basic Sciences: Original Investigations

Effect of Oral Creatine Supplementation on Urinary Methylamine, Formaldehyde, and Formate


Author Information
Medicine & Science in Sports & Exercise: October 2005 - Volume 37 - Issue 10 - p 1717-1720
doi: 10.1249/01.mss.0000176398.64189.e6
  • Free


Creatine monohydrate supplementation is widely consumed by competitive athletes and sport leisure participants in attempt to enhance performance, delay fatigue, and improve recovery (22). Short-term (3 months) beneficial effects have also been described in patients suffering from myopathies (10). Two cases of renal dysfunction subsequent to creatine intake have been reported (9,17). However, previous studies from our laboratory have found no deleterious health effects on kidney function in healthy humans submitted to short-, medium-, and long-term supplementation of oral exogenous creatine (13–16).

The conversion of creatine to sarcosine results in cytotoxic agents such as methylamine (23). The latter has been found to be deaminated by semicarbazide-sensitive amine oxidase (SSAO, EC to produce formaldehyde (26) (Fig. 1). Methylamine and formaldehyde are two well-known cytotoxic agents, the presence of which can be revealed by urine analyses (4,12,25,26).

FIGURE 1—Schematic pathways of creatine and creatinine degradation in the human body. All products and metabolic steps are not shown. Compounds that are framed have been assayed in urine before and after creatine supplementation. SSAO, semicarbazide amine oxidase.
FIGURE 1—Schematic pathways of creatine and creatinine degradation in the human body. All products and metabolic steps are not shown. Compounds that are framed have been assayed in urine before and after creatine supplementation. SSAO, semicarbazide amine oxidase.

Based on a review paper by Wyss and Kaddurah-Daouk (23), a French Agency (AFSSA) (1) claimed unequivocally that excess consumption of creatine and creatinine might induce derived carcinogenic and mutagenic compounds that could put athletes and consumers of exogenous creatine at risk (

To shed light on those allegations, we investigated the appearance of methylamine, formaldehyde, and formate, the main metabolite of formaldehyde, in urine of healthy humans who received oral creatine supplementation.


Twenty healthy male subjects, aged 24.1 ± 1.3 yr (mean ± SEM), volunteered and gave their free consent to the following protocol, which was approved by the medical ethic committee of the Faculty of Medicine (Free University of Brussels). For 14 d, the subjects consumed 21 g of creatine monohydrate (Flamma, Italy) daily, divided into three doses of 7 g each (morning, noon, evening), dissolved in water or fruit juice. The purity of creatine monohydrate has been tested by gas chromatography (99.9%) and found to be devoid of any detectible level of sarcosine as tested by enzymatic reaction. Energy intake was recorded by a food questionnaire over seven continuous days. Most foods were weighed before cooking and eating. Dietary intakes were assessed by Prodiet 5.1 (Proform, France), professional software that displays the nutrient analysis of any food or combination of selected foods. After that period of food stabilization (mean 3353 kcal, 54% carbohydrate, 31% fat, and 15% protein), the subjects were asked to remain on their usual diet for 2 wk. Twenty-four-hour urine collection was obtained before creatine intake and at the end of creatine supplementation. Venous blood samples were drawn after an overnight fast before creatine feeding and at the end of creatine supplements. All samples (urine and plasma) were stored at −20°C until analyses were done.

Creatine and creatinine were determined in plasma and urine using an enzymatic colorimetric test PAP (Boehringer Mannheim-Roche, Germany). Formaldehyde concentrations in urine were determined by high-performance liquid chromatography by derivatization of 2,4-dinitrophenylhydrazine (4). Formate concentrations in urine were assayed by an enzymatic method using formate dehydrogenase and NAD+ (6). Urine methylamine was determined by a stable isotope dilution gas chromatography-mass spectrometry method. We developed this from a gas chromatography procedure that used derivatization with isobutyl chloroformate (11). Albumin concentration in urine was determined by an immunochemical technique using specific monoclonal antiserum (Turbiquant, Behring). To allow for urine volume intra- and interindividual variation, urinary values were expressed as the 24-h excretion rate.

When the values followed the Gaussian distribution (Kolmogorov–Smirnov test), the concentration differences before and after creatine feeding were tested by the Student’s t-test. For data that was not normally distributed, the t-test was applied after logarithmic transformation. The results are reported as means and SEM. The statistical significance was fixed at P ≪ 0.05, two tailed.


Table 1 shows the data obtained on creatine and creatinine concentrations in plasma and urine samples before and after creatine feeding. After an overnight rest following the last intake of creatine, there was a significant increase in venous plasma creatine level (7.2-fold of the basal level) and there was no effect on plasma creatinine level. Creatine urine excretion rates were also highly elevated (141-fold of the basal level) after creatine feeding with no significant changes of the creatinine output. Approximately 77% of the daily dose of ingested creatine was released in the final urine. The albumin urine excretion rate was not affected by creatine supplementation (Table 1).

Mean values (± SEM) of plasma and urine contents before and after creatine supplementation.

Table 1 also includes the modifications of urine excretion of formaldehyde, formate, and methylamine before and after creatine supplementation. Twenty-four-hour urine output of methylamine and formaldehyde increased 9.2- and 4.5-fold, respectively (P < 0.001), after creatine feeding with no increase in formate excretion. After creatine feeding, there was no correlation between plasma creatine and urine methylamine (r2 = 0.025, P = not significant (NS)) or formaldehyde (r2 = 0.017, P = NS).


The results of the present investigation indicate that short-term, high-dose oral creatine ingestion in healthy subjects enhances the mechanisms leading to the conversion of creatine to sarcosine and then to methylamine, the latter one giving rise to formaldehyde. The conversion of formaldehyde to formate should be rather rapid in cells, the latter representing indirectly the production of the former substrate (3). Using rat and mice models, Yu and Deng demonstrated that in vivo deamination of methylamine produces formaldehyde and hydrogen peroxyde, which are both recognized as cytotoxic substances (4,24). Moreover, the inhibition of SSAO, the enzyme that converts methylamine into formaldehyde, enhances the urine output of methylamine after creatine feeding in mice (4,24). Consequently, these authors hypothesized that long-term administration of large quantities of creatine as an ergogenic supplement would increase the production of methylamine and subsequently formaldehyde, both being potentially cytotoxic in renal glomeruli (4,24). Our results support this hypothesis in humans.

Despite the 9.2-fold increase in methylamine urine excretion induced by creatine ingestion, this level did not reach the normal upper limit values from healthy humans, up to 35 mg·d−1 (mean ± 3 SD) (12). After creatine supplementation, urine formate excretion remained below the upper range (14–20 mg·d−1) reported in healthy subjects (2,7,19). However, with creatine supplementation, the urine excretion of formaldehyde increased 4.5-fold of the basal rate. It has been claimed that formaldehyde is a mutagenic and genotoxic agent that reduces the rate of DNA synthesis (20); however, in human, besides our present results, there are not yet available data on the upper limit of the urinary level of formaldehyde that would indirectly support a mutagenic effect in vivo.

Because creatine is transformed to sarcosine by microbial enzymatic reactions (23), it is likely that methylamine is formed in the intestine and is therefore potentially harmful to the integrity of the intestinal epithelium. Methylamine is toxic to human endothelial cells and forms patchlike lesions (27) and even causes kidney damage (26). In mammals, SSAO activity has been found in various tissues associated with the vascular system (5,8). Therefore, it is likely that the deamination of methylamine occurs in the circulation. It could also be speculated that this flooding of methylamine in the blood, together with SSAO, might produce formaldehyde favoring microangiopathy in the renal glomeruli (8,25).

Our subjects consumed a total amount of 294 g creatine monohydrate during 14 d without any modification of glomerular membrane permeability as assessed by their albumin urine excretion rate (9.78 ± 1.93 mg·24 h−1 before creatine; 6.97 ± 1.15 mg·24 h−1 after creatine). The upper limit in healthy humans is 25 mg·24 h−1. Albuminuria has long been known to be associated with specific renal abnormality and is now recognized as an early test for vascular endothelial damage (18). Despite the fact that formaldehyde and methylamine excretion rates were increased, respectively, 4.5- and 9.2-fold after high-dose of creatine supplementation, there was no detectable consequence of glomerulonephropathy. In this context, it has been shown, at least in rats, that formaldehyde administration in drinking water supplied ad libitum during 2 yr can produce specific carcinogenic effects on various organs and tissues (21). This raises the question of the duration of the supplementation. In a previous study, we did not observe any adverse effect of a long-term (up to 5 yr) creatine supplementation in humans (14). Moreover, the present study has only addressed 2-wk supplementation with high-dose creatine (21 g·d−1). The more standard procedure of oral creatine is based on 2–5 g·d−1 after an initial 5 d at a higher dose. Thus, there is reason to believe that lower doses of creatine supplementation would reduce the impact on urinary methylamine and formaldehyde excretion. However, even if systematic deleterious effects could not be observed, it cannot be excluded that systematic production of low extra doses of cytotoxic agents never induces any occurrence of nephropathy. Clearly, epidemiological data are required to evaluate the potential risks over a larger cohort of individuals. But in terms of results of the present investigation, caution should be applied. Kidney function of the patients and healthy subjects supplemented with creatine on a regular basis should be systematically monitored throughout the ingestion period.

In conclusion, short-term, high-dose oral creatine supplementation in young healthy subjects increases urinary excretion of methylamine and formaldehyde within the normal range for a healthy population. In the conditions of the current study, increased urinary methylamine and formaldehyde excretion did not result in impaired renal function. Further studies are needed to evaluate whether long-term creatine supplementation, indeed, is harmless in all individuals.


1. AFSSA. Assessment of the risks of creatine on the consumer and of the veracity of the claims relating to sports performance and the increase of muscle mass. Available at
2. Berode, M., T. Sethre, T. Laubli, and H. Savolainen. Urinary methanol and formic acid as indicators of occupational exposure to methyl formate. Int. Arch. Occup. Environ. Health. 73:410–414, 2000.
3. Boeniger. M. F. Formate in urine as a biological indicator of formaldehyde exposure: a review. Am. Ind. Hyg. Assoc. J. 48:900–908, 1987.
4. Deng, Y., F. Boomsma, and P. H. Yu. Deamination of methylamine and aminoacetone increases aldehydes and oxidative stress in rats. Life Sci. 63:2049–2058, 1998.
5. Garpenstrand, H., M. Bergqvist, D. Brattstrom, et al. Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients. Med. Oncol. 21:241–250, 2004.
6. Grady, S., and J. Osterloh. Improved enzymic assay for serum formate with colorimetric endpoint. J. Anal. Toxicol. 10:1–5, 1986.
7. Kage, S., K. Kudo, H. Ikeda, and N. Ikeda. Simultaneous determination of formate and acetate in whole blood and urine from humans using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 805:113–117, 2004.
8. Kinemuchi, H., H. Sugimoto, T. Obata, N. Satoh, and S. Ueda. Selective inhibitors of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity in mammalian tissues. Neurotoxicology 25:325–335, 2004.
9. Koshy, K. M., E. Griswold, and E. E. Schneeberger. Interstitial nephritis in a patient taking creatine. N. Engl. J. Med. 340:814–815, 1999.
10. Louis, M., J. Lebacq, J. R. Poortmans, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 27:604–610, 2003.
11. Lundh, T., and B. Akesson. Gas chromatographic determination of primary and secondary low-molecular-mass aliphatic amines in urine using derivatization with isobutyl chloroformate. J. Chromatogr. 617:191–196, 1993.
12. Mitchell, S. C., and A. Q. Zhang. Methylamine in human urine. Clin. Chim. Acta 312:107–114, 2001.
13. Poortmans, J. R., H. Auquier, V. Renaut, A. Durussel, M. Saugy, and G. R. Brisson. Effect of short-term creatine supplementation on renal responses in men. Eur. J. Appl. Physiol. Occup. Physiol. 76:566–567, 1997.
14. Poortmans, J. R., and M. Francaux. Long-term oral creatine supplementation does not impair renal function in healthy athletes. Med. Sci. Sports Exerc. 31:1108–1110, 1999.
15. Poortmans, J. R., and M. Francaux. Renal dysfunction accompanying oral creatine supplements. Lancet 352:234, 1998.
16. Poortmans, J. R., and M. Francaux. Renal implications of exogenous creatine monohydrate supplementation. Am. J. Sports Med. 4:212-216, 2002.
17. Pritchard, N. R., and P. A. Kalra. Renal dysfunction accompanying oral creatine supplements. Lancet 351:1252–1253, 1998.
18. Remuzzi, G., and J. J. Weening. Albuminuria as early test for vascular disease. Lancet 365:556–557, 2005.
19. Schmidt. F. H. [Faulty measurement of urinary glucose concentration by polarization]. Dtsch. Med. Wochenschr. 92:2025–2027, 1967.
20. Slikker, W. J., M. E. Andersen, M. S. Bogdanffy, et al. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol. Appl. Pharmacol. 201:226–294, 2004.
21. Soffritti, M., F. Belpoggi, L. Lambertin, M. Lauriola, M. Padovani, and C. Maltoni. Results of long-term experimental studies on the carcinogenicity of formaldehyde and acetaldehyde in rats. Ann. N. Y. Acad. Sci. 982:87–105, 2002.
22. Terjung, R. L., P. Clarkson, E. R. Eichner, et al. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med. Sci. Sports Exerc. 32:706–717, 2000.
23. Wyss, M., and R. Kaddurah-Daouk. Creatine and creatinine metabolism. Physiol. Rev. 80:1107–1213, 2000.
24. Yu, P. H., and Y. Deng. Potential cytotoxic effect of chronic administration of creatine, a nutrition supplement to augment athletic performance. Med. Hypotheses. 54:726–728, 2000.
25. Yu, P. H., S. Wright, E. H. Fan, Z. R. Lun, and D. Gubisne-Harberle. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim. Biophys. Acta 1647:193–199, 2003.
26. Yu, P. H., and D. M. Zuo. Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury. Atherosclerosis 120:189–197, 1996.
27. Yu, P. H., and D. M. Zuo. Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes. Diabetes 42:594–603, 1993.


©2005The American College of Sports Medicine